In a recent clinical trial, tolDCs generated from monocytes by vitaminD3 followed by dexamethasone and loaded with proinsulin peptide C19-A3 were tested to restore immune tolerance in long-term T1D patients, demonstrating feasibility, safety, tolerability and mechanistic efficacy of this novel therapeutic intervention strategy engaging innate immunity (47). The gene discussed is INS; the disease is type 1 diabetes mellitus.